✦ LIBER ✦

Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk

✍ Scribed by Campbell D. Joyner; Ron J.G. Peters; Rizwan Afzal; Susan Chrolavicius; Shamir R. Mehta; Keith A.A. Fox; Christopher B. Granger; Maria Grazia Franzosi; Marcus Flather; Andrzej Budaj; Jean-Pierre Bassand; Salim Yusuf

Book ID: 116191642
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 266 KB
Volume: 157
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2008.10.028

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Frequency, Predictors, and Outcomes of D

Frequency, Predictors, and Outcomes of Drug-Eluting Stent Utilization in Patients With High-Risk Non–ST-Segment Elevation Acute Coronary Syndromes

✍ David E. Kandzari; Matthew T. Roe; E. Magnus Ohman; Sarah Milford-Beland; Anita 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 118 KB

Comparison of Effectiveness of Enoxapari

Comparison of Effectiveness of Enoxaparin Versus Unfractionated Heparin to Reduce Silent and Clinically Apparent Acute Myocardial Infarction in Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndrome

✍ Sanjit Jolly; Mary Tan; Aurora Mendelsohn; David Fitchett; Paul W. Armstrong; An 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Cigarette smoking status and outcome amo

Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: Effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide

✍ David Hasdai; David R. Holmes Jr; Douglas A. Criger; Eric J. Topol; Robert M. Ca 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 615 KB

Design and rationale of the MICHELANGELO

Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 758 KB

Randomized evaluation of the safety and

Randomized evaluation of the safety and efficacy of enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

✍ S.G. Goodman; D. Fitchett; P.W. Armstrong; M. Tan; A. Langer 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Efficacy and safety of enoxaparin compar

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial

✍ Harvey D. White; Neal S. Kleiman; Kenneth W. Mahaffey; Yuliya Lokhnygina; Karen 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 333 KB